提出了一种定量方法来排名优势,弱点,机遇,和威胁(SWOT)的改良安卡拉痘苗病毒(MVA)作为大流行前和大流行流感疫苗的平台。采用层次分析法(AHP)对SWOT因素进行两两比较,确定SWOT因素的优先次序。采访了流感疫苗领域的关键意见领袖(KOL),以收集独特的数据集来评估该平台的市场潜力。本研究的目的,评估MVA平台用于开发新一代大流行性流感疫苗的商业潜力,是通过使用SWOT和AHP相结合的分析方法来完成的。SWOT-AHP模型的应用表明,KOL认为其优势比劣势更重要,机遇,和威胁。特别是,不需要佐剂的MVA的固有免疫原性能力是增加该平台的商业吸引力的最重要因素。对载体疫苗和抗载体免疫的关注被认为是其最重要的弱点,这可能会降低该平台的公共卫生价值。此外,本研究结果的评估强调了这个平台的威胁和机会同样重要的作用。这项研究进一步强调了流感疫苗市场未满足的需求,这可以通过实施MVA平台来解决。在临床试验中广泛使用MVA显示了该载体作为大流行前和大流行流感以及其他呼吸道病毒威胁的疫苗平台的巨大前景。此外,从临床试验的结果看来,MVA对于开发针对病原体的疫苗特别有吸引力,或者只有不够有效的疫苗,是可用的。
A quantitative method is presented to rank strengths, weaknesses, opportunities, and threats (SWOT) of modified vaccinia virus Ankara (MVA) as a platform for pre-pandemic and pandemic influenza vaccines. Analytic hierarchy process (AHP) was applied to achieve pairwise comparisons among SWOT factors in order to prioritize them. Key opinion leaders (KOLs) in the influenza vaccine field were interviewed to collect a unique dataset to evaluate the market potential of this platform. The purpose of this study, to evaluate commercial potential of the MVA platform for the development of novel generation pandemic influenza vaccines, is accomplished by using a SWOT and AHP combined analytic method. Application of the SWOT-AHP model indicates that its strengths are considered more important by KOLs than its weaknesses, opportunities, and threats. Particularly, the inherent immunogenicity capability of MVA without the requirement of an adjuvant is the most important factor to increase commercial attractiveness of this platform. Concerns regarding vector vaccines and anti-vector immunity are considered its most important weakness, which might lower public health value of this platform. Furthermore, evaluation of the results of this study emphasizes equally important role that threats and opportunities of this platform play. This study further highlights unmet needs in the influenza vaccine market, which could be addressed by the implementation of the MVA platform. Broad use of MVA in clinical trials shows great promise for this vector as vaccine platform for pre-pandemic and pandemic influenza and threats by other respiratory viruses. Moreover, from the results of the clinical trials seem that MVA is particularly attractive for development of vaccines against pathogens for which no, or only insufficiently effective vaccines, are available.